Meet Inspiring Speakers and Experts at our 3000+ Global Conference Series Events with over 1000+ Conferences, 1000+ Symposiums
and 1000+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.

Explore and learn more about Conference Series : World's leading Event Organizer

Back

Saeed M. Nagash

King Abdulaziz University, Jeddah, Saudi Arabia

Title: Investigating Human Mammaglobin-A as a Potential Prognostic Marker in Breast Cancer.

Biography

Biography: Saeed M. Nagash

Abstract

Breast cancer (BC) stands out as the most diagnosed cancers in women. Therefore, it is important to diagnose BC patients at the early stages. Human Mammaglobin (MAM-A) is recently shown to specifically express in BC and its increased expression were found in primary breast cancer comparing with undetectable or low levels in non-breast tumors or normal breast tissue. Our aim was to investigate the level of expression for MAM-A as prognostic marker, and its correlation with the clinicopathological characteristics of BC patients. A set of 746 cases of BC, including 371 cases of lymph node (LN) positive, were employed. The immunohistochemistry staining of MAM-A was scored manually under a light microscope based on the intensity of the patterns measured stained slides by Automated Immunohistochemistry (IHC) slide staining system. The results showed significant increase in expression of cytoplasmic MAM-A, associated with triple negative, HER2 expressions and hormone receptor phenotypes, and p-values were (p<0.001), (p<0.01), (p=0.021) respectively. However, nuclear MAM-A expression showed no significant correlation with any clinicopathological features in this study. Moreover, Kaplan-Meier analysis showed no significant difference in survival behaviour with positive expression of cytoplasmic or nuclear MAM-A and no association with tumor recurrence were observed. Therefore, our results showed that MAM-A may act as prognosis marker for some type of BC that may involve triple negative, hormone receptor and HER2 phenotype.